DUSA gains preliminary injunction against Biofrontera

27 December 2018

DUSA Pharmaceuticals, a wholly-owned subsidiary of Sun Pharmaceutical Industries (BSE: 524715), has been granted preliminary injunctive relief by a federal district court prohibiting defendants Germany-based skin cancer specialist Biofrontera (FSE: B8F) and its subsidiaries from using DUSA's confidential and proprietary trade secret information.

Sun Pharma shares ended down 2.23%on Wednesday at 414 rupees on the BSE, while Biofrontera fell as much as 10% to 4.78 euros early afternoon today.

DUSA had filed a lawsuit against the Biofrontera defendants earlier this year in the US District Court for the District of Massachusetts. The lawsuit alleges trade secret misappropriation and patent infringement of DUSA's photodynamic therapy (PDT) patents, US 9,723,991 and US 8,216,289, covering DUSA's product, Levulan Kerastick (aminolevulinic acid HCl) for topical solution, 20% used with DUSA's BLU-U Blue Light Photodynamic Therapy Illuminator.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK